Patient Registry Software MarketSize, Share & Industry Analysis, 2026-2034By Registry TypeBy Software TypeBy ApplicationBy FunctionalityBy Deployment Mode

Patient registry software is a category of health information technology used to systematically collect, store and analyze structured patient data tied to a specific disease, procedure, medical product or care pathway over time. It is delivered as standalone applications or as modules integrated into broader electronic health record and population-health platforms, hosted either on a vendor's cloud infrastructure or within a customer's own data center. Buyers include hospital systems, government health agencies, private payers, pharmaceutical and medical device companies, and academic or clinical research centers that need longitudinal patient data for care management, quality reporting or post-market surveillance.

The global patient registry software market stood at USD 2200 million in 2025. A forecast-period rate of 11.5% takes it to USD 5860 million by 2034, and the study reports every year in between, passing USD 1350 million in 2020, USD 2020 million in 2024, USD 2453 million in 2026 and USD 3792 million in 2030.

20% of 2025 revenue sits in Cardiovascular Registry, worth USD 440 million and rising to USD 1055 million at 18% by 2034, the largest registry type line in both years. Growth is fastest in Rare Disease Registry at 14.78% and slowest in Other Disease Registries at 9.61%. Cancer Registry, Rare Disease Registry and Medical Device Registry take share over the period; Cardiovascular Registry, Diabetes Registry, Other Disease Registries, Health Service Registry and Drug Registry give it up while still growing in absolute terms.

Cut by software type, the largest line is Integrated: 65% of 2025 revenue, worth USD 1430 million, and 73% at USD 4278 million by 2034. It is also the fastest-growing line on this axis at 12.95%, so the split concentrates over the period instead of balancing. Both this axis and the registry type one divide the same revenue, which is why they are alternative views, not components.

The regional order runs from North America at 44% of 2025 revenue down to Middle East and Africa at 5%. North America is worth USD 968 million in 2025 and USD 2344 million in 2034; Europe, second at 27%, moves from USD 594 million to USD 1465 million. Share shifts toward Asia Pacific and Latin America over the forecast period, so the regional split repays a close reading.

The 2025 total is arrived at by triangulating published aggregates against category proxies, not by an independent count. Segment, regional and country splits are estimated on the same basis, which bounds the precision of the figures above. Coverage runs to five regions, eight registry type lines and five segmentation axes across a fifteen-year window.

• Revenue grows from USD 2200 million in 2025 to USD 5860 million in 2034, a compound annual rate of 11.5%, having reached USD 2020 million in 2024 from USD 1350 million in 2020.
• Cardiovascular Registry is the largest registry type line at USD 440 million in 2025, a 20% share, reaching USD 1055 million and 18% of revenue by 2034.
• Fastest growth on the registry type axis belongs to Rare Disease Registry: 14.78% a year, USD 220 million to USD 762 million, and a share moving from 10% to 13%.
• The bull case puts 2034 revenue at USD 6739 million and the bear case at USD 4981 million, either side of the USD 5860 million base case, each with its own stated assumption in the full report.
• The largest region is North America, generating USD 968 million in 2025 (44% of the global total) and USD 2344 million by 2034, ahead of Europe at 27%.
• Within North America, the United States is the worked country example, at USD 823 million in 2025; 85.02% of regional revenue in the base year, and USD 1969 million by 2034.
• Every line on all five segmentation axes and in each of the five regions carries its own revenue, share and growth rate for all fifteen years, 2020 through 2034, on a 2025 base.

Three movements define the forecast period in the global patient registry software market: how the registry type mix changes, where regional weight shifts, and the rate at which the total compounds.

Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.

Composition shifts on the registry type axis. Rare Disease Registry grows at 14.78% across 2026-2034 against 9.61% for Other Disease Registries, the widest spread on the registry type axis. Shares follow: 10% to 13% for Rare Disease Registry, 7% to 6.01% for Other Disease Registries. Neither contracts: USD 220 million becomes USD 762 million, USD 154 million becomes USD 352 million. What the spread decides is which of them a supplier's revenue is exposed to.

Growth concentrates in Asia Pacific and Latin America. Asia Pacific moves from 18% of revenue in 2025 to 23% in 2034, worth USD 396 million rising to USD 1348 million; Latin America moves from 6% of revenue in 2025 to 7% in 2034, worth USD 132 million rising to USD 410 million. Against that, North America at 44% moving to 40%, Europe at 27% moving to 25%, Middle East and Africa at 5% moving to 5%, a fall in share, not in revenue. The practical consequence is that regional weighting decides whether a participant matches the market rate or trails it, regardless of how its own revenue reads.

The series never breaks trajectory. Reading the series: USD 1350 million in 2020, USD 2020 million in 2024, USD 2200 million in 2025, USD 2453 million in 2026, USD 3792 million in 2030 and USD 5860 million in 2034. The forecast rate of 11.5% sits against 10.26% over the historical period, so the projection extends an observed trend instead of proposing a new one. The risk in the number sits in the mix assumptions, not in whether the market grows at all, which is where the registry type and regional sections come in.

Rare Disease Registry carries the market's growth rate

Separate the 11.5% into its parts and three show up: an already-large base compounding, the registry type mix moving toward its faster lines, and regional growth landing unevenly.

Downside case: USD 4981 million by 2034, against USD 5860 million in the base case

What the bull case turns on

Concentration on the registry type axis

USD 968 million of 2025 revenue is generated in North America, 44% of the global patient registry software market with USD 2344 million projected for 2034. Among the five regions it ranks first by revenue in both years.

By 2034 the share stands at 40%, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

Within the region the registry type split tracks the global one; 20% of 2025 revenue in Cardiovascular Registry, fastest growth of 14.78% in Rare Disease Registry. Per-axis and per-country detail for North America sits in the full report.

USD 823 million of North America's 2025 revenue is generated in the United States, the region's largest market, reaching USD 1969 million by 2034. At 85.02% of regional revenue in the base year it is not one market among several, the region's trajectory is largely this country's trajectory. Regional revenue of USD 968 million in 2025 and USD 2344 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Demand in the United States follows the registry type mix reported at global level: Cardiovascular Registry is the largest line at 20% of 2025 revenue, moving to 18% by 2034, while Rare Disease Registry grows fastest at 14.78% and takes its share from 10% to 13%. Since 85.02% of North America's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. The full report reports the United States by registry type separately.

The Food and Drug Administration oversees software of this kind under its medical device framework, though most patient registry platforms fall outside device jurisdiction because they organize and report data rather than diagnose or treat. Where a vendor's software instead functions as certified health information technology, it must meet the Office of the National Coordinator's certification criteria and demonstrate that patient data can be structured and exchanged using recognized interoperability standards. Vendors handling protected health information must also satisfy the safeguards set out in HIPAA, covering how data is stored, transmitted and disclosed. State-level privacy statutes can impose further obligations depending on where patients and providers are located. Suppliers marketing registry tools to hospital systems are expected to document these compliance pathways clearly, since procurement teams treat certification and privacy assurances as a baseline purchasing requirement rather than an optional feature.

The suppliers tracked in this study (IBM Corporation (US), IQVIA Holdings (US), OpenText Corporation (Canada), Optum (US), Premier, Inc. (US), ArborMetrix, Inc. (US), FIGmd (US), McKesson Corporation (US), Syneos Health (US), Dacima Software, Inc. (Canada), ifa Systems AG (Germany), Medstreaming- M2S (US), ImageTrend, Inc. (US), Evado Clinical (Australia), WIRB Copernicus Group (US), Global Vision Technologies, Inc. (India), Conduent, Inc. (US) and Elekta AB (Sweden)) compete in the United States across the registry type lines above. Cardiovascular Registry, at 20% of 2025 revenue, is where the volume sits, and Rare Disease Registry, growing at 14.78%, is where position changes hands over the forecast period. Country-level shares and positioning per company sit in the full report.

Within North America, Canada accounts for 14.98% of regional revenue and 6.59% of the global total, worth USD 145 million in 2025 and USD 375 million by 2034.

In Europe, 27% of global revenue puts 2025 at USD 594 million with USD 1465 million projected for 2034. It is a leading region on this axis, second by revenue throughout the period.

Share settles at 25% in 2034, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

The registry type mix reported at global level applies here, with Cardiovascular Registry the largest line at 20% of 2025 revenue and Rare Disease Registry the fastest-growing at 14.78%. Per-axis and per-country detail for Europe sits in the full report.

27.95% of Europe's base-year revenue comes from Germany; USD 166 million, rising to USD 410 million by 2034. 27.95% of the region in the base year makes it the largest market here without making it the region. The region itself runs USD 594 million to USD 1465 million over the same period, and this is the market carrying the country-level detail in the full report.

Composition here matches the global split: the largest line is Cardiovascular Registry at 20% of 2025 revenue, easing to 18% by 2034, and the fastest is Rare Disease Registry at 14.78%, from 10% to 13%. Its 27.95% weight in Europe means those movements carry straight into the regional totals. The full report reports Germany by registry type separately.

Patient registry software sold in Germany sits at the intersection of medical device law and data protection law. Where the software supports clinical decision-making or manages data tied to a regulated device, it can fall under the Medical Device Regulation, requiring the manufacturer to classify the product correctly and demonstrate conformity before affixing a CE mark. Purely administrative or research-oriented registries generally sit outside that regime but remain squarely governed by the General Data Protection Regulation as implemented through German federal and state data protection law, given the sensitivity of health information. Suppliers must show a lawful basis for processing, appropriate technical safeguards and clear data-subject rights handling. Hospitals and research institutions procuring such software typically require documented evidence of both data protection compliance and, where applicable, device conformity before deployment proceeds.

Competition in Germany runs between the suppliers this study tracks: IBM Corporation (US), IQVIA Holdings (US), OpenText Corporation (Canada), Optum (US), Premier, Inc. (US), ArborMetrix, Inc. (US), FIGmd (US), McKesson Corporation (US), Syneos Health (US), Dacima Software, Inc. (Canada), ifa Systems AG (Germany), Medstreaming- M2S (US), ImageTrend, Inc. (US), Evado Clinical (Australia), WIRB Copernicus Group (US), Global Vision Technologies, Inc. (India), Conduent, Inc. (US) and Elekta AB (Sweden). Cardiovascular Registry, at 20% of 2025 revenue, is where the volume sits, and Rare Disease Registry, growing at 14.78%, is where position changes hands over the forecast period.

The United Kingdom is sized at USD 143 million in 2025, rising to USD 352 million by 2034; 6.5% of global revenue and 24.07% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

4.86% of global revenue is generated in France; USD 107 million in 2025, reaching USD 264 million in 2034, and 18.01% of Europe.

18% of the global patient registry software market sits in Asia Pacific in 2025, worth USD 396 million rising to USD 1348 million in 2034. It is a mid-sized region on this axis, third by revenue throughout the period.

By 2034 the share has moved up to 23%, because it outgrows the market's 11.5%; the revenue added here is disproportionate to where the region started.

Segment composition follows the global pattern: Cardiovascular Registry largest at 20% of 2025 revenue, Rare Disease Registry fastest at 14.78%. Per-axis and per-country detail for Asia Pacific sits in the full report.

The largest single market in Asia Pacific is Japan, at USD 119 million in 2025 and USD 377 million in 2034. Its 30.05% of base-year regional revenue leads the region, though enough sits elsewhere that Asia Pacific is not a proxy for it. Against regional totals of USD 396 million in 2025 and USD 1348 million in 2034, it is the country the full report breaks out in detail.

The registry type pattern in Japan is the global one: 20% of 2025 revenue in Cardiovascular Registry, 18% by 2034, against 14.78% growth in Rare Disease Registry taking it from 10% to 13%. With 30.05% of Asia Pacific concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Per-registry type revenue for Japan appears on its own in the full report.

Japan regulates software used in healthcare settings primarily through the Pharmaceuticals and Medical Devices Act, administered with the Pharmaceuticals and Medical Devices Agency reviewing higher-risk products. A registry platform used strictly for data collection and reporting, without diagnostic or treatment functions, generally falls outside device approval and is instead shaped by guidance from the Ministry of Health, Labour and Welfare on handling medical information securely. Suppliers must ensure patient data is protected in line with Japan's personal information protection framework, with particular attention to consent and cross-border transfer rules given how frequently registry data is aggregated for research. Where a registry tool is bundled with or feeds into a certified medical device, the vendor must align its data-handling design with that device's own approval conditions rather than treating the software as a separate, unregulated component.

The suppliers tracked in this study (IBM Corporation (US), IQVIA Holdings (US), OpenText Corporation (Canada), Optum (US), Premier, Inc. (US), ArborMetrix, Inc. (US), FIGmd (US), McKesson Corporation (US), Syneos Health (US), Dacima Software, Inc. (Canada), ifa Systems AG (Germany), Medstreaming- M2S (US), ImageTrend, Inc. (US), Evado Clinical (Australia), WIRB Copernicus Group (US), Global Vision Technologies, Inc. (India), Conduent, Inc. (US) and Elekta AB (Sweden)) compete in Japan across the registry type lines above. Cardiovascular Registry, at 20% of 2025 revenue, is where the volume sits, and Rare Disease Registry, growing at 14.78%, is where position changes hands over the forecast period.

China is sized at USD 99 million in 2025, rising to USD 404 million by 2034; 4.5% of global revenue and 25% of Asia Pacific. It is reported separately from Japan across every segmentation axis in the full report.

USD 132 million of 2025 revenue is generated in Latin America, 6% of the global patient registry software market on the way to USD 410 million by 2034. Among the five regions it ranks fourth by revenue in both years.

7% of global revenue sits here by 2034, up from the 2025 level, on growth above the market's own 11.5%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.

Segment composition follows the global pattern: Cardiovascular Registry largest at 20% of 2025 revenue, Rare Disease Registry fastest at 14.78%. Revenue for Latin America is broken out by every segmentation axis and by country in the full report.

Brazil is the largest market within Latin America, generating USD 59 million in 2025 and projected to reach USD 180 million by 2034. 44.7% of the region in the base year makes it the largest market here without making it the region. Against regional totals of USD 132 million in 2025 and USD 410 million in 2034, it is the country the full report breaks out in detail.

The registry type pattern in Brazil is the global one: 20% of 2025 revenue in Cardiovascular Registry, 18% by 2034, against 14.78% growth in Rare Disease Registry taking it from 10% to 13%. With 44.7% of Latin America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Per-registry type revenue for Brazil appears on its own in the full report.

Brazil's health regulator, ANVISA, oversees software that qualifies as a medical device, and registry platforms are evaluated against that boundary based on whether they merely compile patient data or actively support diagnosis or treatment decisions. Software found to fall within device scope must be classified according to risk and registered before commercial distribution, with documentation demonstrating quality management and clinical safety. Registries used purely for administrative or epidemiological tracking are more likely to sit outside ANVISA's device pathway but remain subject to the Lei Geral de Proteção de Dados, Brazil's general data protection law, which governs consent, storage and transfer of patient information. Suppliers serving public and private hospital networks are generally expected to document their regulatory position clearly, since institutional buyers treat that determination as part of standard due diligence before adoption.

Competition in Brazil runs between the suppliers this study tracks: IBM Corporation (US), IQVIA Holdings (US), OpenText Corporation (Canada), Optum (US), Premier, Inc. (US), ArborMetrix, Inc. (US), FIGmd (US), McKesson Corporation (US), Syneos Health (US), Dacima Software, Inc. (Canada), ifa Systems AG (Germany), Medstreaming- M2S (US), ImageTrend, Inc. (US), Evado Clinical (Australia), WIRB Copernicus Group (US), Global Vision Technologies, Inc. (India), Conduent, Inc. (US) and Elekta AB (Sweden). Cardiovascular Registry, at 20% of 2025 revenue, is where the volume sits, and Rare Disease Registry, growing at 14.78%, is where position changes hands over the forecast period.

1.5% of global revenue is generated in Mexico; USD 33 million in 2025, reaching USD 107 million in 2034, and 25% of Latin America.

In Middle East and Africa, 5% of global revenue puts 2025 at USD 110 million with USD 293 million projected for 2034. That makes it the fifth-largest region covered, in 2025 and again in 2034.

By 2034 the share stands at 5%, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

Segment composition follows the global pattern: Cardiovascular Registry largest at 20% of 2025 revenue, Rare Disease Registry fastest at 14.78%. Per-axis and per-country detail for Middle East and Africa sits in the full report.

The largest single market in Middle East and Africa is Saudi Arabia, at USD 39 million in 2025 and USD 103 million in 2034. 35.45% of the region in the base year makes it the largest market here without making it the region. Regional revenue of USD 110 million in 2025 and USD 293 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Composition here matches the global split: the largest line is Cardiovascular Registry at 20% of 2025 revenue, easing to 18% by 2034, and the fastest is Rare Disease Registry at 14.78%, from 10% to 13%. Because the country carries 35.45% of Middle East and Africa, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Saudi Arabia carries its own registry type breakdown in the full report.

The Saudi Food and Drug Authority governs medical device software in the Kingdom, and a patient registry platform is assessed against that authority's criteria for whether it performs a diagnostic, monitoring or treatment-support function or instead serves a purely administrative and reporting role. Software judged to meet the device definition must be classified by risk and registered before it can be marketed to healthcare providers, with the supplier expected to demonstrate quality management practices aligned with the Authority's requirements. Registries operating outside that definition still fall under the Kingdom's personal data protection law, which sets obligations for consent, storage and cross-border handling of patient information. Vendors supplying hospitals and ministries typically need to show a clear regulatory classification alongside evidence of data protection compliance before a contract can proceed.

IBM Corporation (US), IQVIA Holdings (US), OpenText Corporation (Canada), Optum (US), Premier, Inc. (US), ArborMetrix, Inc. (US), FIGmd (US), McKesson Corporation (US), Syneos Health (US), Dacima Software, Inc. (Canada), ifa Systems AG (Germany), Medstreaming- M2S (US), ImageTrend, Inc. (US), Evado Clinical (Australia), WIRB Copernicus Group (US), Global Vision Technologies, Inc. (India), Conduent, Inc. (US) and Elekta AB (Sweden) are the suppliers covered in Saudi Arabia. Volume sits in Cardiovascular Registry at 20% of 2025 revenue; movement sits in Rare Disease Registry at 14.78% growth.

1.27% of global revenue is generated in South Africa; USD 28 million in 2025, reaching USD 73 million in 2034, and 25.45% of Middle East and Africa.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by registry type, software type, application, functionality, deployment mode, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.